selective TLR7/8 inhibitor (dimer stabilizer)

in Ph. I for lupus (oral twice-daily)

from screening for TLR7/8-selective agents

J. Pharmacol. Exp. Ther., Mar. 1, 2021

EMD Serono/Merck KGaA, Billerica, MA


11. The EMD Serono/Merck KGaA toll-like receptors TLR7/TLR8 inhibitor M5049 is an oral, twice-daily anti-inflammatory agent currently in a Ph. I trial for Lupus. The molecule potently blocks both…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: